Integrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Integrum yıllık ortalama 23.4% oranında kazançlarını artırırken, Medical Equipment sektöründe kazançlar growing at 22.9% annual. Gelirler yılda ortalama 30.8% oranında büyüyor .

Anahtar bilgiler

23.4%

Kazanç büyüme oranı

30.0%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	6.2%
Gelir büyüme oranı	30.8%
Özkaynak getirisi	-1.3%
Net Marj	-2.2%
Sonraki Kazanç Güncellemesi	04 Dec 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

Aug 30

Gelir ve Gider Dağılımı

Integrum nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

OM:INTEG B Gelir, gider ve kazançlar (SEK Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Jul 24	110	-2	92
30 Apr 24	110	4	88
31 Jan 24	101	-4	86
31 Oct 23	87	-19	85
31 Jul 23	80	-18	88
30 Apr 23	78	-16	85
31 Jan 23	81	-7	84
31 Oct 22	76	7	75
31 Jul 22	66	19	65
30 Apr 22	61	21	55
31 Jan 22	52	16	46
31 Oct 21	49	16	41
31 Jul 21	49	2	39
30 Apr 21	44	-2	35
31 Jan 21	39	-4	35
31 Oct 20	35	-9	36
31 Jul 20	31	-14	36
30 Apr 20	28	-16	38
31 Jan 20	23	-20	41
31 Oct 19	21	-24	44
31 Jul 19	25	-24	45
30 Apr 19	26	-25	46
31 Jan 19	26	-23	44
31 Oct 18	22	-23	40
31 Jul 18	17	-23	37
30 Apr 18	19	-18	34
31 Jan 18	20	-17	33
31 Oct 17	24	-10	31
31 Jul 17	22	-9	28
30 Apr 17	23	-6	26
31 Jan 17	24	0	21
30 Apr 16	18	0	16
30 Apr 15	17	0	14
30 Apr 14	19	2	12

Kaliteli Kazançlar: INTEG B şu anda kârlı değil.

Büyüyen Kar Marjı: INTEG B şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: INTEG B kârlı değildir, ancak son 5 yılda zararlarını yılda 23.4% oranında azaltmıştır.

Büyüme Hızlandırma: INTEG B 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: INTEG B kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 31% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: INTEG B hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -1.32% ) sahiptir.

Integrum Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First quarter 2025 earnings released

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Consensus revenue estimates fall by 18%

Price target decreased by 19% to kr62.50

Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

New major risk - Share price stability

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.

Investor sentiment improved over the past week

Integrum's (STO:INTEG B) Earnings Aren't As Good As They Appear